AngioDynamics, Inc. (NASDAQ:ANGO) Stake Raised by Fmr LLC

Fmr LLC increased its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 105.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,779 shares of the medical instruments supplier’s stock after buying an additional 27,031 shares during the quarter. Fmr LLC owned about 0.13% of AngioDynamics worth $411,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. grew its stake in shares of AngioDynamics by 3.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 326,820 shares of the medical instruments supplier’s stock worth $2,543,000 after purchasing an additional 11,599 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in AngioDynamics by 37.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 230,156 shares of the medical instruments supplier’s stock worth $1,791,000 after purchasing an additional 62,496 shares during the period. Segall Bryant & Hamill LLC grew its position in AngioDynamics by 142.7% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock valued at $7,091,000 after buying an additional 535,958 shares in the last quarter. Quest Partners LLC acquired a new position in AngioDynamics during the 3rd quarter valued at about $285,000. Finally, Royce & Associates LP raised its position in shares of AngioDynamics by 10.8% during the 3rd quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier’s stock worth $7,672,000 after buying an additional 96,138 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ANGO. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a report on Tuesday, December 10th. Canaccord Genuity Group decreased their price target on AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a research note on Friday, October 4th.

AngioDynamics Trading Down 3.9 %

Shares of NASDAQ ANGO opened at $8.58 on Friday. AngioDynamics, Inc. has a twelve month low of $5.26 and a twelve month high of $9.58. The firm has a 50-day moving average of $7.26 and a two-hundred day moving average of $7.03. The company has a market capitalization of $348.64 million, a price-to-earnings ratio of -1.41 and a beta of 0.68.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. The business had revenue of $67.50 million during the quarter, compared to analyst estimates of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business’s quarterly revenue was down 14.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.12) earnings per share. As a group, research analysts predict that AngioDynamics, Inc. will post -0.41 earnings per share for the current year.

Insider Activity at AngioDynamics

In related news, CEO James C. Clemmer acquired 20,000 shares of the business’s stock in a transaction on Monday, October 7th. The shares were purchased at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the acquisition, the chief executive officer now owns 681,582 shares in the company, valued at approximately $4,109,939.46. This represents a 3.02 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders purchased 22,568 shares of company stock worth $135,847 in the last quarter. 5.40% of the stock is owned by company insiders.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.